Stay updated with breaking news from Solara Active Pharma Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The Board of Directors of Solara Active Pharma Sciences Limited, at its meeting held today have approved the financial results of the company for the period ended March 31, 2023 - Q4FY23 and FY2023.
On the Bombay Stock Exchange (BSE), 1256 stocks advanced, 2337 declined and 166 remained unchanged with advance decline ratio of 0.54, indicating a negative closing of stocks in broader markets.
Solara Active Pharma Sciences Ltd announced the successful completion EU-GMP Inspection, carried out jointly by the SUKL, Ministry of Health of the Czech Republic and INFARMED, Portugal at the multi-product manufacturing facility at Cuddalore.
According to the findings of a new Future Market Insights (FMI) report, the global Ibuprofen API Market crossed US$ 626.2 Million in 2022 and is expected to grow at a CAGR of 3% to reach US$ 772.2 Million by 2029. The key drivers of the Ibuprofen API market are the ongoing need for low-cost nonsteroidal anti-inflamm...
USFDA clears Solara Active's Visakhapatnam facility. The US Food and Drug Administration has cleared Solara Active Pharma Sciences Ltd's new multipurpose active pharmaceutical ingredient manufacturing facility at Visakhapatnam, Andhra Pradesh, with no observation, the company said in an exchange filing.